Summary
This paper reviews the effects on myocardial contractility, left ventricular afterload and left ventricular distensibility induced by the following phosphodiesterase inhibitors: Enoximone, piroximone, RO 13-6438, amrinone and milrinone. For all these compounds, direct positive inotropic effects have been shown in experimental studies. For amrinone and milrinone, a direct stimulating effect on myocardial contractility has been demonstrated by an increase in dP/dtmax when intracoronary applications of the compounds were performed. A direct stimulating effect on the myocardium was also demonstrated for enoximone and piroximone by analyzing the systolic pressure versus end-systolic volume ratio.
For all of the phosphodiesterase inhibitors, a marked decrease of systemic vascular resistance has been observed indicating direct peripheral vasodilation. Although it has been demonstrated that phosphodiesterase inhibition increases left ventricular distensibility, the nature of this effect is not clear. For most of the phosphodiesterase inhibitors an increase in myocardial oxygen requirements was demonstrated due to overall contractility increase. However, these phosphodiesterase inhibitors induce increased coronary blood flow in excess so that a direct effect of these compounds on the coronary vasculature has been postulated. The clinical significance of such changes, however, remains unclear.
Similar content being viewed by others
References
Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N Engl J Med 314:290
Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanism of action and recent clinical developments. N Engl J Med 314:3498
Kereiakes D, Chatterjee K, Parmley WW et al. (1984) Intravenous and oral DML 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol 4:884
Axelrod RJ, DeMarco T, Dae M, Botvinick E, Chatterjee K (1987) Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol 9:1124
Daly PA, Chatterjee K, Viquerat CE et al. (1983) RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure. Chest 84:408
Simonton CA, Chatterjee K, Cody RJ et al. (1985) Milrinone in congestive heart failure: Acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 6:453
Chatterjee K, Parmley WW (1977) The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 19:301–325
Alousi AA, Stankus GP, Stuart JC, Walton LH (1983) Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 5:804
Kariya T, Willia LJ, Dage RC (1982) Biochemical studies on the mechanism of cardiotonic activity of RMI 17043 (1,3-dihydro-4-methyl-5-4(methylthio)-(benzoyl)-2H-imidizone-2-one) (abstr). Fed Proc 41:1310
Dage RC, Hsieh CP, Kariya T, Schnettler RA (1985) Cardiotonic activity on MDL 19,205 (4-ethyl-1,3-dihydro-5-(4-pyridinyl-carbonyl)-2H-imidazol-2-one) (abstr). Fed Proc 42:1131
Janicki JS, Shroff SG, Weber KT (1987) Physiologic response to the inotropic and vasodilator properties of enoximone. Am J Cardiol 60:15C-20C
Suga H, Sagawa K, Shoukas AA (1973) Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 32:314
Crawford MH, Sorensen SG, Richards KL, Sedums M (1983) Demonstrations of combined vasodilator-inotropic effects of RMI 17,043 in patients with reduced left ventricular heart failure. Circulation 67:823
Mancini D, LeJemtel T, Sonnenblick EP (1985) Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 56:8B
Benotti JR, Grossman W, Braunwald E et al. (1978) Hemodynamic assessment of amrinone: A new inotropic agent. N Engl J Med 299:1373
Kereiakes D, Viquerat C, Lanzer P, Botvinick E, Spangenberg R, Buckingham M, Parmley WW, Chatterjee K (1984) Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. American Heart Journal 108:1278
Salzman SH, Wolfson S, Jackson B, Schechter E (1971) Epinephrine infusion in man. Standardization, normal response, and abnormal response in idiopathic hypertrophic subaortic stenosis. Circulation 43:137
Horshen RJ, Cuddy TE (1975) Dose-responsiveness relation between therapeutic levels of serum digoxin and systolic time intervals (abstr). Am J Cardiol 35:469
Roebel LE, Dage RC, Cheng HC, Woodward J (1982) Characterization of the cardiovascular activities of a new cardiotonic agents, MDL 17,043 (1,3-dihydro-4-methyl-5E40(methylthio)-benzoyl)-2H-imidazol-2-one. J Cardiovasc Pharmacol 4:721
Cody RG, Muller FB, Kubo SH et al. (1986) Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation 73:124
Monrad ES, McKay RG, Baim DS, Colucci WS, Fifer MA, Heller GV, Royal HD, Grossman W (1984) Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 70:1030
Herman HC, Ruddy TD, Dec GW, Strauss HW, Boucher CA, Fifer MA (1987) Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside. Circulation 75:1214
Viquerat C, Kereiakes D, Morris L, Daly P, Wexman M, Frank P, Parmley WW, Chatterjee K (1985) Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a New Inotropic Vasodilator Agent, in Patients with Severe Heart Failure. J Am Coll Cardiol 5:326
Benotti JR, Grossman W, Braunwald E, Carabello BA (1980) Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 62:28
Monrad ES, Baim DS, Smith HS, Lanoue A, Branwald E, Grossman W (1985) Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 71:972
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chatterjee, K. Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics. Basic Res Cardiol 84, 213–224 (1989). https://doi.org/10.1007/BF02650361
Issue Date:
DOI: https://doi.org/10.1007/BF02650361